Vilobelimab, marketed as Gohibic, has received Emergency Use Authorization from the US Food and Drug Administration (FDA) for patients with severe COVID-19 symptoms. The drug, an anti-C5a monoclonal antibody that targets an inflammatory pathway believed to be involved in COVID-19 progression, is authorized for use in hospitalized patients with COVID-19 within 48 hours of starting invasive mechanical ventilation or extracorporeal membrane oxygenation, according to the FDA announcement.
Source: JAMA Online First